KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Non-Current Deferred Tax Liability: 2017-2018

Historic Non-Current Deferred Tax Liability for Amneal Pharmaceuticals (AMRX) over the last 1 years, with Dec 2018 value amounting to $1.2 million.

  • Amneal Pharmaceuticals' Non-Current Deferred Tax Liability fell 64.16% to $1.2 million in Q4 2018 from the same period last year, while for Dec 2018 it was $1.2 million, marking a year-over-year decrease of 64.16%. This contributed to the annual value of $1.2 million for FY2018, which is 64.16% down from last year.
  • As of Q4 2018, Amneal Pharmaceuticals' Non-Current Deferred Tax Liability stood at $1.2 million, which was down 33.11% from $1.8 million recorded in Q3 2018.
  • Amneal Pharmaceuticals' 5-year Non-Current Deferred Tax Liability high stood at $3.3 million for Q4 2017, and its period low was $1.2 million during Q4 2018.
  • Its 2-year average for Non-Current Deferred Tax Liability is $2.2 million, with a median of $2.1 million in 2018.
  • Data for Amneal Pharmaceuticals' Non-Current Deferred Tax Liability shows a maximum YoY tumbled of 64.16% (in 2018) over the last 5 years.
  • Over the past 2 years, Amneal Pharmaceuticals' Non-Current Deferred Tax Liability (Quarterly) stood at $3.3 million in 2017, then plummeted by 64.16% to $1.2 million in 2018.
  • Its Non-Current Deferred Tax Liability was $1.2 million in Q4 2018, compared to $1.8 million in Q3 2018 and $2.5 million in Q2 2018.